Cardiology

New research highlights another benefit of COVID-19 vaccination, reported researchers.

Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.

Your daily dose of the clinical news you may have missed.

Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.

Your daily dose of the clinical news you may have missed.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.

In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.

Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.

Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

Your daily dose of the clinical news you may have missed.

Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.

Your daily dose of the clinical news you may have missed.

Topline KARDIA-2 findings showed zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB.

Your daily dose of the clinical news you may have missed.

Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.

The risk for cardiovascular outcomes increased with more frequent reported cannabis use per month, according to results from a large national study.

Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Older adults with normal BP levels in China were approximately 40% less likely to develop HTN when using a salt substitute for 2 years, according to a new study.

Your daily dose of the clinical news you may have missed.